Portal de Periódicos da CAPES

Increased risk of thiopurine‐related adverse events in elderly patients with IBD

2019; Wiley; Volume: 50; Issue: 7 Linguagem: Inglês

10.1111/apt.15458

1365-2036

Margalida Calafat, Míriam Mañosa, Fiorella Cañete, Elena Ricart, Eva Iglesias, Marta Calvo, Francisco Rodríguez‐Moranta, Carlos Taxonera, Pilar Nos, Francisco Mesonero, María Dolores Martín‐Arranz, Miguel Mínguez, Javier P. Gisbert, Santiago García‐López, Ruth de Francisco, Fernando Gomollón, Xavier Calvet, Esther García-Planella, Montserrat Rivero, J Martínez-Cadilla, Federico Argüelles‐Arias, Lara Arias García, Marta Cimavilla, Yamile Zabana, Eugeni Domènech,

Viral-associated cancers and disorders

Summary Background Thiopurines are the most widely used immunosuppressants in IBD although drug‐related adverse events (AE) occur in 20%‐30% of cases. Aim To evaluate the safety of thiopurines in elderly IBD patients Methods Cohort study including all adult patients in the ENEIDA registry who received thiopurines. Patients were grouped in terms of age at the beginning of thiopurine treatment, specifically in those who started thiopurines over 60 years or between 18 and 50 years of age. Thiopurine‐related AEs registered in the ENEIDA database were compared. Results Out of 48 752 patients, 1888 started thiopurines when over 60 years of age and 15 477 under 50 years of age. Median treatment duration was significantly shorter for those who started thiopurines >60 years (13 [IQR 2‐55] vs 32 [IQR 5‐82] months; P < .001). Patients starting >60 years had higher rates of all types of myelotoxicity, digestive intolerance and hepatotoxicity. Thiopurines were discontinued due to AEs (excluding malignancies and infections) in more patients starting >60 years (67.2% vs 63.1%; P < .001). Elderly age and female sex were independent risk factors for most AEs. Conclusion In elderly IBD patients, thiopurines are associated with an increased risk of non‐infectious, non‐neoplastic, AEs.